Drug Type Small molecule drug |
Synonyms LSD1/HDAC6 dual inhibitors, Lysine specific demethylase 1 and histone deacetylase 6 inhibitors, N-hydroxy-4-((4-((((1R,2S)-2-phenylcyclopropyl) amino)methyl)-1H-pyrazol-1-yl)methyl)benzamide hydrogen bromide. + [2] |
Target |
Mechanism HDAC6 inhibitors(Histone deacetylase 6 inhibitors), KDM1A inhibitors(Lysine-specific histone demethylase 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Start Date29 Apr 2024 |
Sponsor / Collaborator [+1] |
Start Date08 Apr 2022 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Locally Advanced Malignant Solid Neoplasm | Phase 2 | US | Jubilant Therapeutics, Inc.Startup | 08 Apr 2022 |
Metastatic Solid Tumor | Phase 2 | US | Jubilant Therapeutics, Inc.Startup | 08 Apr 2022 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
NCT05268666 (PRNewswire) Manual | Phase 1 | 11 | aprnnmdtws(jtwznnrleh) = Platelet decrease is the only adverse event above grade 1 observed in these patients, no AEs (Adverse Events) of anemia has been observed, which is potentially due to the positive benefit of inhibition of HDAC6 in erythrocytes. Also, there are no reports of Dysgeusia, an adverse event that has been observed with LSD1-only inhibitors. kvccntuxsu (muakwthywy ) | Positive | 08 Jan 2024 | ||
(NSCLC) |